|
Study Comparing Rovalpituzumab Tesirine Vs Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemo |
III |
|
|
Study Comparing Tislelizumab + Platinum And Fluoropyrimidine Versus Placebo Plus Platinum And Fluoropyrimidine As First-Line Treatment In Patients With Locally Advanced Unresectable Or Metastatic Gastric or GEJ Adenocarcinoma (BGBA317- 305) |
III |
|
|
Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy (11282 SGN35-015) |
I |
|
|
Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer (I5B-MC-JGDP) |
II |
|
|
Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer |
III |
|
|
Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer; (AFT-19) |
III |
|
|
Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Adult Pancreatic Adenocarcinoma (CanStem111P) |
III |
|
|
Study Of Concurrent Durvalumab And Radiation Therapy Followed By Adjuvant Durvalumab In Patients With Urothelial Cancer (T2-4 N0-2 M0) Of The Bladder (BTCRC GU15-023) |
I |
|
|
Study of FOLFIRINOX plus Ramucirumab versus FOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients (GI14-198) |
II |
|
|
Study Of High Dose Interleukin 2 Vs High Dose Interleukin 2 Plus Entinostat In Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289) |
II |
|
|
Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (PCYC-1128-CA) |
I |
|
|
Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (PCYC-1128-CA) |
I |
|
|
Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO) |
II |
|
|
Study of mFolfox6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatci Colorectal Cancer (GI004) |
III |
|
|
Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer (EA2165) |
II |
|
|
Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (N0577) |
III |
|
|
Study Testing the Addition of Nivolumab Pre and Post Nephrectomy in Patients with Renal Cell Carcinoma (EA8143) |
III |
|
|
The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry |
III |
|
|
Trial Comparing Paclitaxel, Ifosfamide, and Cisplatin with High-Dose Chemo Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors (A031102) |
III |
|
|
Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (GU006) |
II |
|
|
Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy (S1418) |
III |
|
|
Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (AFT-38) |
III |
|
